β2-Adrenergic receptor gene polymorphisms in the relapse of myasthenia gravis with thymus abnormality

References

• Suzuki S, Nishimoto T, Kohno M, et al. Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis. J Neuroimmunol 2013;258:61–6.
   PubMed Web of Science ®Google Scholar
• Wakata N, Iguchi H, Sugimoto H, et al. Relapse of ocular symptoms after remission of myasthenia gravis–a comparison of relapsed and complete remission cases. Clin Neurol Neurosurg 2003;105:75–7.
   PubMed Web of Science ®Google Scholar
• Mao, ZF, Mo, XA, Qin C, et al. Course and prognosis of myasthenia gravis: a systematic review. Eur J Neurol 2010;17:913–21.
   PubMed Web of Science ®Google Scholar
• Maggi L, Andreetta F, Antozzi C, et al. Thymoma-associated myasthenia gravis: outcome, clinical and pathological correlations in 197 patients on a 20-year experience. J Neuroimmunol 2008;201–202:237–44.
   PubMed Web of Science ®Google Scholar
• Kobilka BK, Frielle T, Dohlman HG, et al. Delineation of the intronless nature of the genes for the human and hamster beta2-adrenergic receptor and their putative promoter regions. J Biol Chem 1987;262:7321–7.
   PubMed Web of Science ®Google Scholar
• Bhatnagar P, Guleria R, Kukreti R. Pharmacogenetics of β2-agonists: key focus on signaling pathways. Pharmacogenomics 2006;7:919–33.
   PubMed Web of Science ®Google Scholar
• Kohm AP, Sanders VM. Norepinephrine and beta2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. Pharmacol Rev 2001;53(4):487–525.
   PubMed Web of Science ®Google Scholar
• Nakai A, Hayano Y, Furuta F, et al. Control of lymphocyte egress from lymph nodes through β2-adrenergic receptors. J Exp Med 2014;211:2583–98.
   PubMed Web of Science ®Google Scholar
• Guereschi MG, Araujo LP, et al. Beta2-adrenergic receptor signaling in CD4+ Foxp3+ regulatory T cells enhances their suppressive function in a PKA-dependent manner. Eur J Immunol 2013;43:1001–12.
   PubMed Web of Science ®Google Scholar
• Xu BY, Huang D, Pirskanen R, et al. Beta2-adrenergic receptor gene polymorphisms in myasthenia gravis (MG). Clin Exp Immunol 2000;119:156–60.
   PubMed Web of Science ®Google Scholar
• Wang LL, Xie YC, Hou SF, et al. Role of β2-adrenergic receptor polymorphisms in pathogenesis of myasthenia gravis. Chin J Neurol 2009;42:828–32.
   Google Scholar
• Forleo C, Resta N, Sorrentino S, et al. Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med 2004;117:451–8.
   PubMed Web of Science ®Google Scholar
• Monraats PS, Pires NM, Agema WR, et al. Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation 2005;112:2417–25.
   PubMed Web of Science ®Google Scholar
• Wenjuan Y, Yujun L, Ceng Y. Association of single nucleotide polymorphisms of β2-adrenergic receptor gene with clinicopathological features of pancreatic carcinoma. Acta Histochem 2013;115:198–203.
   PubMed Web of Science ®Google Scholar
• Xu B, Arlehag L, Rantapää-Dahlquist SB, et al. beta2-adrenergic receptor gene single-nucleotide polymorphisms are associated with rheumatoid arthritis in northern Sweden. Scand J Rheumatol 2004;33:395–8.
   PubMed Web of Science ®Google Scholar
• Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol 2014;175:408–18.
   PubMed Web of Science ®Google Scholar
• Hsu HS, Huang CS, Huang BS, et al. Thymoma is associated with relapse of symptoms after transsternal thymectomy for myasthenia gravis. Interact Cardiovasc Thorac Surg 2006;5:42–6.
   PubMedGoogle Scholar
• Men LN, Liu WB, Chen ZG, et al. Prognostic factors related to recurrence after extended thymectomy in patients with myasthenia gravis. Zhonghua Yi Xue Za Zhi 2008;88:1446–9.
   PubMedGoogle Scholar
• Jaretzki A III, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16–23.
   PubMed Web of Science ®Google Scholar
• De Perrot M, Liu J, Bril V, et al. Prognostic significance of thymomas in patients with myasthenia gravis. Ann Thorac Surg 2002;74:1658–62.
   PubMed Web of Science ®Google Scholar
• Niino M, Kikuchi S, Miyagishi R, et al. An examination of the association between beta2 adrenergic receptor polymorphisms and multiplesclerosis. Mult Scler 2002;8:475–8.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang W, Chen Y, et al. T helper type 17 cells expand in patients with myasthenia-associated thymoma. Scand J Immunol 2012;l76:54–61.
   Web of Science ®Google Scholar
• Gradolatto A, Nazzal D, Truffault F, et al. Both Treg cells and Tconv cells are defective in the myasthenia gravis thymus: roles of IL-17 and TNF-α. J Autoimmun 2014;52:53–63.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Inaba Y, Nakazawa Y, et al. Reduction in peripheral regulatory T cell population in childhood ocular type myasthenia gravis. Brain Dev 2015;37:808–16.
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Parillon X, Zeng S, et al. Deficiency of autophagy in dendritic cells protects against experimental autoimmune encephalomyelitis. J Biol Chem 2014;289:26525–32.
   PubMed Web of Science ®Google Scholar
• Wu C, Aichinger M, Nedjic J, et al. Thymic epithelial cells use macroautophagy to turn their inside out for CD4 T cell tolerance. Autophagy 2013;9:931–2.
   PubMed Web of Science ®Google Scholar